ASCO 2023 Highlights on adjuvant osimertinib in resected EGFR mutated NSCLC: The ADAURA trial
Reporting from ASCO 2023, Thomas John discusses the results from the ADAURA study of adjuvant osimertinib in patients with resected EGFR mutated (EGFRm) stage IB–IIIA non-small cell lung cancer (NSCLC).
Abstract: LBA3 - Overall survival analysis from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR mutated (EGFRm) stage IB–IIIA non-small cell lung cancer (NSCLC), presented by Roy Herbst. Simultaneously published in The New England Journal of Medicine.
The ESMO Educational Videos series features renowned experts in oncology sharing their knowledge on a variety of subjects. Full series here https://oncologypro.esmo.org/oncology...
Produced by the European Society for Medical Oncology
http://oncologypro.esmo.org
Watch video ASCO 2023 Highlights on adjuvant osimertinib in resected EGFR mutated NSCLC: The ADAURA trial online without registration, duration hours minute second in high quality. This video was added by user European Society for Medical Oncology (ESMO) 08 June 2023, don't forget to share it with your friends and acquaintances, it has been viewed on our site 3,252 once and liked it 52 people.